Survival analysis of advanced non-small cell lung cancer patients with acquired EGFR T790M mutation receiving Osimertinib treatment
Objective To analyze the survival of patients with advanced non-small cell lung cancer (NSCLC) with acquired epidermal growth factor receptor (EGFR) T790M mutation who received treatment with Osimertinib. Methods A retrospective analysis was conducted on the data of 100 NSCLC patients who received sequential Osimertinib treatment at Dongguan Tungwah Hospital from April 2017 to December 2019. Record the patient's survival status,conduct univariate and multivariate analysis on the patient's survival status,and record the adverse reactions during the treatment process. Results The median progression-free survival time of all patients was 20.98 months,and the median total survival time was 30.97 months. The length of first-line treatment with the first-generation or second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) was an independent factor affecting the survival of T790M mutation patients receiving Osimertinib sequentially (P<0.05). The difference of progression-free survival time and total survival time between the first-generation or second-generation EGFR-TKIs treatment with a duration of ≤ 11 months and>11 months was statistically significant (P<0.05). In the process of using Osimertinib,a total of 60 adverse reactions occurred in all patients. Conclusion The duration of first-line or second-generation EGFR-TKIs treatment is an independent influencing factor on the survival of T790M mutation patients with advanced NSCLC receiving sequential treatment with osimertinib,and the safety of osimertinib treatment is relatively good.
Epidermal growth factor receptorMutationNon-small cell lung cancerOsimertinibSurvival time
万方数据
维普
